Monoclonal Antibodies Report:2009 update

The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commercial evolution out to 2014 and assessing trends by product, company, therapy area, geography, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics.

The global prescription pharmaceutical market is expected to face a decline in sales over 2012 to 2013 as a result of the 'patent cliff'. The patent cliff will impact the small molecule market, in contrast, the mAb market segment will continue to record robust growth.

Over the forecast period monoclonal antibodies are predicted to enjoy double-digit growth while small molecule drugs face declining growth rates. The main barrier to sales growth for small molecules, and particularly in the US, is exposure to material generic competition, which Datamonitor believes will have no effect on mAbs out to 2014.

This attractive growth rate and sales return potential has made mAb companies a prime acquisition target in recent years, even during a period of economic uncertainty, with a number of key acquisitions made during 2008-09.

Read more...

• Nonalcoholic Steatohepatitis (26/04/2010)
• HIV/AIDS (26/04/2010)
• Cardiac Assist Devices (15/02/2010)

• EU Pharmaceutical Forum (11/10/2008)
• Neuropathic Pain (10/10/2008)
• Non-hormonal Treatments for Menopausal Symptoms (10/10/2008)
• Rx-to-OTC Strategies (10/10/2008)
• Asthma (10/10/2008)
• Vaccines for Adults and the Elderly (10/10/2008)
• Fibromyalgia (10/10/2008)
• Novel Therapeutic Approaches in Cardiovascular Medicine (09/10/2008)
• Diagnostics in Neurology (09/10/2008)

---